Hagiwara Solutions to Exhibit at SPS 2019
15.11.2019 12:00:00 EET | Business Wire | Press release
Hagiwara Solutions Co., Ltd. (Elecom group) will exhibit at sps – smart production solution from the 26th to 28th of November 2019, Trade Fair Nuremberg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005082/en/
Introduction Map (Graphic: Hagiwara Solutions)
|
Hagiwara Solutions Co., Ltd. is with Elecom group which is offering solutions with sensing technologies, industrial computers, and SSDs. D-Clue Technologies Co., Ltd. of Elecom group which is good for sensing technologies will join us at sps. |
SEVEN solutions for your own:
-
Coolant Contamination Detection:
How do you manage machine tool coolant for precise products?
You can maintain the coolant correctly, using our live sensing system.
Let us suggest you make precise products with our coolant contamination detection system.
-
AR Goggle Devices:
How do you browse reference documents during your tasks?
Workers with our AR goggles don’t need to worry about it.
The AR goggle device displays instructions inside of the goggle. Easy to browse instructions during your tasks.
Let us suggest you make your hands free in your factories.
-
Sound Sensing for Connector Mating:
How do your workers recognize their mating connectors correctly?
If they fail to mate them, it must affect your manufacturing processes. Our sound sensing system can pick up just click sounds to make their mating assured.
Let us suggest you reduce assembling failures.
-
umati OPC UA Server on Tiny Gateway:
How do you arrange M2M communications?
Old factory machines can communicate with the other machines on the different platforms, using our gateway certified with umati OPC UA which is the world industrial standard.
Let us suggest you arrange M2M communications freely.
-
Rugged PCs, wherever you work:
What computer is good for your tough working environment?
Our rugged PC, ZEROSHOCK TABLET is good for you.
You must be satisfied with its shock resistant, water and dust resistant, and touch operation with gloves on.
In addition, the thickness is only 13.3mm and the weight is only 795g!
Let us suggest you work wherever you are.
-
Maintenance Free PC Which Diagnoses Itself:
What do you think of a predictive maintenance?
You can see computer troubles before something happens to factory machines which Maintenance Free PC controls.
Let us suggest you say “Unexpected troubles are GONE!”
-
The Robustness of SSDs Under Power Fault:
What should you do in case of power fault in your factory?
You may lose data, your computer systems may be damaged under power fault. Our SSDs can solve it with UWF of Windows10.
Let us suggest you protect your systems and data.
Press briefing:
A press briefing will be held by Mr. Hada, Hagiwara Solutions President as below:
|
Date and time: |
Tuesday, 26th of November, 2019; 4:00 – 5:00 PM |
|
Place: |
|
|
Presenter: |
Mr. Jamie Hada, Hagiwara Solutions President
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191115005082/en/
Contact information
Shinobu Apostol ITO
Hagiwara Solutions Co., Ltd.
pr@hagisol.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom